Revolutionary Autoinjector Pushes the Limits of High Viscosity Drug Delivery
Thursday, April 18, 2013
Oval Medical Technologies Ltd announced that a variety of 1100 cPs solutions have been successfully delivered through a 25G thin wall needle, in less than 7 seconds, using their revolutionary autoinjector.
Scientists ID New Kidney Cancer Subtypes
Thursday, April 18, 2013
Breakthrough will help physicians tailor treatment to individual kidney cancer patients, moving cancer care one step closer to personalized medicine.
Metrics Offers Proprietary Pellet Forms for Advanced Drug Release
Thursday, April 18, 2013
Unique pellet formulations help support therapeutic effectiveness of active pharmaceutical ingredients.
Curie-Cancer and Vygon Sign a Partnership Agreement Extension
Tuesday, April 16, 2013
The Curie-Cancer and Vygon partnership will extend over several years and will achieve the development of catheters and implantable ports with increased resistance to nosocomial infections, for launch on the international market.
BioAlliance Pharma’s Sitavig® Receives Market Authorization in the US
Tuesday, April 16, 2013
Authorization from the U.S. FDA for Sitavig® in the treatment of recurring Herpes labialis, marking the successful conclusion to the assessment procedure carried out by the American authorities.
Aushon BioSystems Appoints Industry Veteran Susan Vogt Chief Executive Officer
Tuesday, April 16, 2013
Former SeraCare CEO and Millipore executive to guide strategic direction of life sciences services and technology company.
Gene Signature Can Predict Who Will Survive Chemotherapy
Tuesday, April 16, 2013
An eight gene ‘signature’ can predict length of relapse-free survival after chemotherapy, finds new research in Biomed Central’s open access journal BMC Medicine.
FDA Names Breast Cancer Drug a Breakthrough Therapy
Monday, April 15, 2013
An experimental drug being investigated for the treatment of advanced breast cancer by researchers at UCLA this week received breakthrough therapy designation from the U.S. FDA.
NIH Trial Shows Promising Results in Treating a Lymphoma in Young People
Friday, April 12, 2013
Studies demonstrate that the use of rituximab in the drug regimen may improve treatment.
|
|
|
|
|
|
